InvestorsHub Logo
Followers 10
Posts 4272
Boards Moderated 0
Alias Born 11/12/2012

Re: drkazmd65 post# 107355

Saturday, 01/24/2015 5:15:04 PM

Saturday, January 24, 2015 5:15:04 PM

Post# of 146201

And yes - Ebolacide testing is a wild-card that could change everything here very abruptly.



Yes Ebolacide testing is a wild card. But it's a wild card that could send the price crashing down as easily as it could cause the price to spike up. Most people here seem near certain that Ebolacide2 will work. I'm not so sure the optimism is warranted. The first version of Ebolacide didn't cure any mice. Now they say we understand the virus better, and know the right receptor to use. Well, maybe. Or maybe there's more about the Ebola virus that we still don't know.

I think the major reason Zincfinger dumped his stock and switched from bull to bear, aside from the usual interminable delays, was the choice by NNVC management to focus on Ebolacide. He saw that as trading a near sure thing (Flucide development) for a high risk gamble on Ebolacide. I agree -- it is still the case that more people get killed by influenza than by Ebola, and the right thing to do would have been to concentrate on Flucide. NNVC has too many pots on the stove for such a small company, and is taking a bit risk on Ebolacide. Suppose it doesn't work -- NNVC will just continue with Flucide, right? Except we know that some time before phase 2 trials NNVC will have to sell some of those shares on the shelf and raise some money. It will make a huge difference to current shareholders whether those shares are sold at $10 or ten times as many at $1.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NNVC News